Search Results for: g

Corporate Governance

CORPORATE GOVERNANCE Documents & Charters Audit Committee Charter Compensation Committee Charter Nominating & Corporate Governance Committee Charter Code of Business Conduct & Ethics Corporate Governance Guidelines Other Links View Our Management View Our Board of Directors Committee Composition Audit Compensation Nominating and Corporate Governance Committee Daniel Zabrowski Chair Member Roger Sawhney Member Member Amy Ronneberg

Corporate Governance Read More »

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib for treatment of patients with pancreatic cancer. Elraglusib (9-ING-41) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER Read More »

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

Publications /

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). Read More »